Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
81 Results for "
BTB domain
" in MedChemExpress (MCE) Product Catalog:
Products (81)
81 Results for "BTB domain" in MCE Product Catalog:
3
3 Cited Publications
Target:
Research Areas:
BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
3
3 Cited Publications
BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
Cat. No.: HY-172736
CAS No.: 3005272-36-3
Synonyms: BMS-986458
Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
Cat. No.: HY-161138
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
Cat. No.: HY-177755
CAS No.: 2230406-52-5
Target:
Research Areas:
BCL6-IN-10 is a molecular glue inhibitor targeting the BCL6 BTB domain with an IC50 of 4 nM. BCL6-IN-10 blocks the interaction between BCL6 and transcriptional co-repressors, and induces partial degradation of BCL6 via the ubiquitin-proteasome pathway, thereby de-repressing BCL6 target genes and inhibiting cancer cell proliferation. BCL6-IN-10 can be used in the research of diffuse large B-cell lymphoma .
Cat. No.: HY-177756
CAS No.: 2230406-60-5
BCL6-IN-11 is a potent inhibitor of the BCL6 BTB domain and a partial degrader of BCL6. BCL6-IN-11 inhibits the interaction between the BCL6 BTB domain and BCOR with an IC50 of 6 nM. BCL6-IN-11 can be used for research related to BCL6 degradation in diffuse large B-cell lymphoma (DLBCL) .
Cat. No.: HY-P10543
CAS No.: 857026-08-5
Cat. No.: HY-170301
Target:
Research Areas:
Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC50 of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC50 of 527 nM .
Cat. No.: HY-P701575
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD2; BTB And Kelch domain-Containing Protein 1; Prev. BKLHD1; DKFZP566C134; Kelch Repeat And BTB (POZ) domain Containing 2; KIAA1489; Kelch Repeat And BTB domain-Containing Protein 2; Kelch Repeat And BTB domain Containing 2; BTB And Kelch domain Conta
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701576
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD2; BTB And Kelch domain-Containing Protein 1; Prev. BKLHD1; DKFZP566C134; Kelch Repeat And BTB (POZ) domain Containing 2; KIAA1489; Kelch Repeat And BTB domain-Containing Protein 2; Kelch Repeat And BTB domain Containing 2; BTB And Kelch domain Conta
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701536
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ domain-Containing Protein 3; BTB/POZ Do
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701538
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BTBD9; KIAA1880; BTB domain Containing 9; BTB/POZ domain-Containing Protein 9; DJ322I12.1; BTB (POZ) domain Containing 9
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701537
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ domain-Containing Protein 3; BTB/POZ Do
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P701539
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BTBD9; KIAA1880; BTB domain Containing 9; BTB/POZ domain-Containing Protein 9; DJ322I12.1; BTB (POZ) domain Containing 9
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-208744
CAS No.: 2374712-76-0
BCL6-IN-14 is a BCL6 inhibitor with a Kd value of 41.1 μM for the BCL6 BTB domain. BCL6-IN-14 inhibits Karpas-422 tumors. BCL6-IN-14 can be used in cancer-related research .
Cat. No.: HY-P701577
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD6; Kelch Repeat And BTB (POZ) domain Containing 6; Kelch Repeat And BTB domain Containing 6; DKFZp547E1912; Kelch Repeat And BTB domain-Containing Protein 6; Alternative Protein KBTBD6
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-111381R
CAS No.: 2166387-64-8
Target:
Research Areas:
BI-3812 (Standard) is the analytical standard of BI-3812 (HY-111381). This product is intended for research and analytical applications. BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
Cat. No.: HY-P701578
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD7; Kelch Repeat And BTB (POZ) domain Containing 7; Kelch Repeat And BTB domain Containing 7; DKFZP434E2318; Kelch Repeat And BTB domain-Containing Protein 7; KBTBD7 Protein
Species:
Human
Source:
Sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
